MENDOLARO, MARCO
 Distribuzione geografica
Continente #
NA - Nord America 130
AS - Asia 57
EU - Europa 54
AF - Africa 14
SA - Sud America 14
Totale 269
Nazione #
US - Stati Uniti d'America 128
SG - Singapore 33
IT - Italia 20
CN - Cina 19
IE - Irlanda 15
BR - Brasile 14
CI - Costa d'Avorio 8
DE - Germania 7
SN - Senegal 6
GB - Regno Unito 4
RU - Federazione Russa 3
CA - Canada 2
UZ - Uzbekistan 2
BE - Belgio 1
BG - Bulgaria 1
IL - Israele 1
IN - India 1
IQ - Iraq 1
LT - Lituania 1
PL - Polonia 1
UA - Ucraina 1
Totale 269
Città #
Santa Clara 29
Chandler 22
Singapore 18
Dublin 15
Abidjan 8
Chicago 8
Catania 6
Civitanova Marche 6
Council Bluffs 6
Dakar 6
Beijing 5
Boardman 5
Andover 4
Bremen 4
Cambridge 4
Columbus 4
Des Moines 4
Jacksonville 4
Lawrence 4
The Dalles 4
Dallas 2
Grafing 2
Los Angeles 2
Nanchang 2
Tappahannock 2
Toronto 2
Ashburn 1
Barra Mansa 1
Bauru 1
Brooklyn 1
Brussels 1
Civitavecchia 1
Gravataí 1
Guangzhou 1
Guaíba 1
Itu 1
Jiaxing 1
Krasnodar 1
London 1
Manaus 1
Manchester 1
Miami 1
Milan 1
Monte Azul Paulista 1
Montes Claros 1
Nanjing 1
Nanning 1
New York 1
Oklahoma City 1
Piracicaba 1
Piripiri 1
Rio Grande 1
Shenyang 1
Stornoway 1
São José do Rio Preto 1
Tel Aviv 1
Três Lagoas 1
Vilnius 1
Volta Redonda 1
Warsaw 1
Wilmington 1
Totale 213
Nome #
CLINICAL SIGNIFICANCE OF CYTOMEGALOVIRUS (CMV) INFECTION IN INFLAMMATORY BOWEL DISEASE 88
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis 68
Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis 66
EVALUATION OF CROHN'S DISEASE ACTIVITY BY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING (MRI) 61
Totale 283
Categoria #
all - tutte 1.100
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.100


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202116 0 0 1 0 4 0 4 0 2 4 1 0
2021/202225 2 4 0 0 4 1 4 1 0 0 2 7
2022/202362 4 5 2 10 3 12 0 12 11 0 3 0
2023/202427 2 6 1 0 1 6 0 1 0 1 8 1
2024/2025113 2 11 6 12 25 15 5 7 13 4 9 4
2025/202620 17 2 1 0 0 0 0 0 0 0 0 0
Totale 283